Posted by Michael Wonder on 02 Jun 2017
European Commission approves Bristol-Myers Squibb’s Opdivo (nivolumab) for previously treated locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy
2 June 2017 - Opdivo is now approved in the European Union for eight indications in six distinct tumour types.
Bristol-Myers Squibb Company announced today that the European Commission has approved Opdivo (nivolumab) for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.
Today’s decision makes Opdivo the first Immuno-oncology agent approved in the European Union for the treatment of patients with this common type of bladder cancer.
